CEA [CHINA EASTERN AIRLINES] 6-K: (Original Filing)
[]
YGE [YINGLI GREEN ENERGY CO] 6-K: (Original Filing)
[Yingli Green Energy Reports First Quarter 2013 Results BAODING, China, May 30, 2013 Yingli Green Energy Holding Company Limited (NYSE: YGE) (Yingli Green Energy or the Company), a leading solar energy company and one of the worlds largest vertically integrated photovoltaic manufacturers, which markets its products under the brand Yingli Solar, today announced its unaudited consolidated financial results for]
YGE [YINGLI GREEN ENERGY CO] 6-K: Yingli Green Energy Reports First Quarter 2013 Results
[Yingli Green Energy Reports First Quarter 2013 Results BAODING, China, May 30, 2013 Yingli Green Energy Holding Company Limited (NYSE: YGE) (Yingli Green Energy or the Company), a leading solar energy company and one of the worlds largest vertically integrated photovoltaic manufacturers, which markets its products under the brand Yingli Solar, today announced its unaudited consolidated financial results for]
CHL [CHINA MOBILE] 6-K: (Original Filing)
[Number Page 1.1 Voluntary Announcement, dated May 31, 2013 A-1 -2-]
CHL [CHINA MOBILE] 6-K: Number Page 1.1 Voluntary Announcement, dated May 31,
[Number Page 1.1 Voluntary Announcement, dated May 31, 2013 A-1 -2-]
SMI [SEMICONDUCTOR MANUFACTURING INTERNATIONAL] 6-K: (Original Filing)
[SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION (Incorporated in the Cayman Islands with limited liability) (STOCK CODE: 981) ESTABLISHMENT OF A JOINT VENTURE IN BEIJING, THE PRC ESTABLISHMENT OF THE JOINT VENTURE The Company is pleased to announce that, on 3 June 2013, the Company entered into the Joint Venture Agreement with SMIC Beijing, BIDIMC and ZDG in relation to the establishment of]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2013. First Quarter 2013 Financial Highlights (Year-over-year] [Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration BEIJING, May 30, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next] [Sinovac Appoints New Chief Financial Officer Vice President of Sinovac Named CFO BEIJING, May 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has] []
SMI [SEMICONDUCTOR MANUFACTURING INTERNATIONAL] 6-K: SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION (Incorporated in the Cayman
[SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION (Incorporated in the Cayman Islands with limited liability) (STOCK CODE: 981) ESTABLISHMENT OF A JOINT VENTURE IN BEIJING, THE PRC ESTABLISHMENT OF THE JOINT VENTURE The Company is pleased to announce that, on 3 June 2013, the Company entered into the Joint Venture Agreement with SMIC Beijing, BIDIMC and ZDG in relation to the establishment of]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2013 Financial Results
[Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2013. First Quarter 2013 Financial Highlights (Year-over-year] [Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration BEIJING, May 30, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next] [Sinovac Appoints New Chief Financial Officer Vice President of Sinovac Named CFO BEIJING, May 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has] []
